ArticleBMC bioinformatics2025
GNNMutation: a heterogeneous graph-based framework for cancer detection.
Article in BMC bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundWhen genes are translated into proteins, mutations in the gene sequence can lead to changes in protein structure and function as well as in the interactions between proteins. These changes can disrupt cell function and contribute to the development of tumors. In this study, we introduce a novel approach based on graph neural networks that jointly considers genetic mutations and protein interactions for cancer prediction. We use DNA mutations in whole exome sequencing data and construct a heterogeneous graph in which patients and proteins are represented as nodes and protein-protein interactions as edges. Furthermore, patient nodes are connected to protein nodes based on mutations in the patient's DNA. Each patient node is represented by a feature vector derived from the mutations in specific genes. The feature values are calculated using a weighting scheme inspired by information retrieval, where whole genomes are treated as documents and mutations as words within these documents. The weighting of each gene, determined by its mutations, reflects its contribution to disease development. The patient nodes are updated by both mutations and protein interactions within our noval heterogeneous graph structure. Since the effects of each mutation on disease development are different, we processed the input graph with attention-based graph neural networks.
resultsWe compiled a dataset from the UKBiobank consisting of patients with a cancer diagnosis as the case group and those without a cancer diagnosis as the control group. We evaluated our approach for the four most common cancer types, which are breast, prostate, lung and colon cancer, and showed that the proposed framework effectively discriminates between case and control groups.
conclusionsThe results indicate that our proposed graph structure and node updating strategy improve cancer classification performance. Additionally, we extended our system with an explainer that identifies a list of causal genes which are effective in the model's cancer diagnosis predictions. Notably, some of these genes have already been studied in cancer research, demonstrating the system's ability to recognize causal genes for the selected cancer types and make predictions based on them.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.